Li Zilin
No. 1 Teaching Hospital, Norman Bethune College of Medicine, Jilin University, Changchun, Jilin, China.
Front Endocrinol (Lausanne). 2025 Jan 13;15:1469268. doi: 10.3389/fendo.2024.1469268. eCollection 2024.
Thyroid-associated ophthalmopathy (TAO), an autoimmune disease closely related to thyroid dysfunction, remains a challenging ophthalmic condition among adults. Its clinical manifestations are complex and diverse, and disease progression can lead to exophthalmos, diplopia, exposure keratitis, corneal ulceration, and compressive optic neuropathy, resulting in irreversible vision damage or even blindness. Traditional treatment methods for TAO, including glucocorticoids, immunosuppressants, and radiation therapy, often have limitations and side effects, making this disease problematic in ophthalmology. As a result, the development of novel targeted drugs has become a research hotspot for addressing the pathogenesis of TAO. A range of novel targeted drugs, such as teprotumumab and tocilizumab, have been successfully developed and demonstrated remarkable efficacy in relieving inflammation and managing this disease. In addition, some drug candidates and molecular targets identified in the TAO model have shown promising prospects. This article briefly reviews the potential new strategies for future clinical treatment and the progress of new drug therapies for TAO.
甲状腺相关性眼病（TAO）是一种与甲状腺功能障碍密切相关的自身免疫性疾病，在成年人中仍然是一种具有挑战性的眼科疾病。其临床表现复杂多样，疾病进展可导致眼球突出、复视、暴露性角膜炎、角膜溃疡和压迫性视神经病变，从而导致不可逆的视力损害甚至失明。TAO的传统治疗方法，包括糖皮质激素、免疫抑制剂和放射治疗，往往存在局限性和副作用，使得这种疾病在眼科领域成为难题。因此，开发新型靶向药物已成为解决TAO发病机制的研究热点。一系列新型靶向药物，如替普罗单抗和托珠单抗，已成功研发并在减轻炎症和治疗该疾病方面显示出显著疗效。此外，在TAO模型中确定的一些候选药物和分子靶点也显示出了有前景的前景。本文简要综述了TAO未来临床治疗的潜在新策略和新药治疗的进展。
